Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

How much of the sediment in Gale crater's central mound was fluvially transported?

Thomson BJ, Buczkowski DL, Crumpler LS, Seelos KD, Fassett CI.

Geophys Res Lett. 2019 May 28;46(10):5092-5099. doi: 10.1029/2018GL081727. Epub 2019 Apr 29.

PMID:
31359893
2.

Young adults' attitudes to sharing whole-genome sequencing information: a university-based survey.

Barnard P, Sharples S, Thomson BJ, Garibaldi JM.

BMC Med Genomics. 2019 Apr 16;12(1):55. doi: 10.1186/s12920-019-0499-2.

3.

Testing for hepatitis C virus infection in UK prisons: What actually happens?

Jack K, Thomson BJ, Irving WL.

J Viral Hepat. 2019 Jun;26(6):644-654. doi: 10.1111/jvh.13071. Epub 2019 Feb 27.

PMID:
30702194
4.

The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England.

Harrison GI, Murray K, Gore R, Lee P, Sreedharan A, Richardson P, Hughes AJ, Wiselka M, Gelson W, Unitt E, Ratcliff K, Orton A, Trinder K, Simpson C, Ryder SD, Oelbaum S, Foster GR, Christian A, Smith S, Thomson BJ, Reynolds R, Harris M, Hickman M, Irving WL.

Addiction. 2019 Jun;114(6):1113-1122. doi: 10.1111/add.14569. Epub 2019 Mar 12.

PMID:
30694582
5.

Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients.

Bradley C, Scott RA, Cox E, Palaniyappan N, Thomson BJ, Ryder SD, Irving WL, Aithal GP, Guha IN, Francis S.

Eur Radiol. 2019 Jun;29(6):3100-3107. doi: 10.1007/s00330-018-5788-1. Epub 2018 Nov 30.

6.

Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?

Abo-Zeid Y, Urbanowicz RA, Thomson BJ, Irving WL, Tarr AW, Garnett MC.

Int J Pharm. 2018 Aug 25;547(1-2):572-581. doi: 10.1016/j.ijpharm.2018.06.027. Epub 2018 Jun 13.

PMID:
29908332
7.

Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin.

Baloch K, Chen L, Memon AA, Dexter L, Irving W, Ilyas M, Thomson BJ.

Antivir Chem Chemother. 2017 Apr;25(1):2-10. doi: 10.1177/2040206616686894. Epub 2017 Jan 1.

8.

Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes.

Ko JS, Matharoo-Ball B, Billings SD, Thomson BJ, Tang JY, Sarin KY, Cai E, Kim J, Rock C, Kimbrell HZ, Flake DD 2nd, Warf MB, Nelson J, Davis T, Miller C, Rushton K, Hartman AR, Wenstrup RJ, Clarke LE.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1107-1113. doi: 10.1158/1055-9965.EPI-16-0958. Epub 2017 Apr 4.

9.

Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatment.

Howes N, Lattimore S, Irving WL, Thomson BJ.

Open Forum Infect Dis. 2016 Jan 6;3(1):ofv218. doi: 10.1093/ofid/ofv218. eCollection 2016 Jan.

10.

Nottingham Health Science Biobank: a sustainable bioresource.

Matharoo-Ball B, Thomson BJ.

Biopreserv Biobank. 2014 Oct;12(5):312-6. doi: 10.1089/bio.2014.0056.

PMID:
25340939
11.

Serum autoantibody measurement for the detection of hepatocellular carcinoma.

Middleton CH, Irving W, Robertson JF, Murray A, Parsy-Kowalska CB, Macdonald IK, McElveen J, Allen J, Healey GF, Thomson BJ, Ryder SJ, Holdenrieder S, Chapman CJ.

PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.

12.

Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells.

Saeed A, Baloch K, Brown RJ, Wallis R, Chen L, Dexter L, McClure CP, Shakesheff K, Thomson BJ.

Clin Exp Immunol. 2013 Nov;174(2):265-73. doi: 10.1111/cei.12174.

13.

Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.

Pritchett J, Harvey E, Athwal V, Berry A, Rowe C, Oakley F, Moles A, Mann DA, Bobola N, Sharrocks AD, Thomson BJ, Zaitoun AM, Irving WL, Guha IN, Hanley NA, Hanley KP.

Hepatology. 2012 Sep;56(3):1108-16. doi: 10.1002/hep.25758.

14.

Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice.

Grishchenko M, Grieve RD, Sweeting MJ, De Angelis D, Thomson BJ, Ryder SD, Irving WL; Trent HCV Study Group.

Int J Technol Assess Health Care. 2009 Apr;25(2):171-80. doi: 10.1017/S0266462309090229. Epub 2009 Mar 31.

15.

Hepatitis C virus: the growing challenge.

Thomson BJ.

Br Med Bull. 2009;89:153-67. doi: 10.1093/bmb/ldp003. Epub 2009 Jan 30. Review.

PMID:
19181740
16.

Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C.

Jack K, Willott S, Manners J, Varnam MA, Thomson BJ.

Aliment Pharmacol Ther. 2009 Jan;29(1):38-45. doi: 10.1111/j.1365-2036.2008.03872.x. Epub 2008 Oct 13.

17.

Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.

Thomson BJ, Kwong G, Ratib S, Sweeting M, Ryder SD, De Angelis D, Grieve R, Irving WL; Trent HCV Study Group.

J Viral Hepat. 2008 Apr;15(4):271-8. Epub 2007 Dec 11.

PMID:
18086181
18.

A closer look at water-related geologic activity on Mars.

McEwen AS, Hansen CJ, Delamere WA, Eliason EM, Herkenhoff KE, Keszthelyi L, Gulick VC, Kirk RL, Mellon MT, Grant JA, Thomas N, Weitz CM, Squyres SW, Bridges NT, Murchie SL, Seelos F, Seelos K, Okubo CH, Milazzo MP, Tornabene LL, Jaeger WL, Byrne S, Russell PS, Griffes JL, Martínez-Alonso S, Davatzes A, Chuang FC, Thomson BJ, Fishbaugh KE, Dundas CM, Kolb KJ, Banks ME, Wray JJ.

Science. 2007 Sep 21;317(5845):1706-9.

19.

Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study.

Neal KR; Trent Hepatitis C Study Group, Ramsay S, Thomson BJ, Irving WL.

Gut. 2007 Aug;56(8):1098-104. Epub 2007 Mar 7.

20.

Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding.

Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK.

J Virol. 2006 Sep;80(17):8695-704.

21.

Clinical pathways for patients with newly diagnosed hepatitis C - what actually happens.

Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland CA, Ryder SD, Thomson BJ, Pringle M, Bicknell M, Hippisley-Cox J.

J Viral Hepat. 2006 Apr;13(4):264-71.

PMID:
16611193
22.

Caspase-independent killing of Burkitt lymphoma cell lines by rituximab.

Daniels I, Abulayha AM, Thomson BJ, Haynes AP.

Apoptosis. 2006 Jun;11(6):1013-23.

PMID:
16544097
23.

The effect of three-dimensional co-culture of hepatocytes and hepatic stellate cells on key hepatocyte functions in vitro.

Thomas RJ, Bhandari R, Barrett DA, Bennett AJ, Fry JR, Powe D, Thomson BJ, Shakesheff KM.

Cells Tissues Organs. 2005;181(2):67-79.

PMID:
16534201
24.

Hepatitis C virus infection.

Thomson BJ, Finch RG.

Clin Microbiol Infect. 2005 Feb;11(2):86-94. Review.

25.

Loss of cytomegalovirus-specific immunological memory in a patient with thymoma.

Huissoon AP, Davies G, Cox RA, Sloper CM, Thomson BJ, Robins RA.

Clin Exp Immunol. 2002 Aug;129(2):297-301.

26.

CD95 (Fas) expression is regulated by sequestration in the Golgi complex in B-cell lymphoma.

Haynes AP, Daniels I, Abhulayha AM, Carter GI, Metheringham R, Gregory CD, Thomson BJ.

Br J Haematol. 2002 Aug;118(2):488-94.

PMID:
12139737
27.

Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity.

Curran R, Jameson CL, Craggs JK, Grabowska AM, Thomson BJ, Robins A, Irving WL, Ball JK.

J Gen Virol. 2002 Jan;83(Pt 1):11-23.

PMID:
11752696
28.

Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection.

Grabowska AM, Lechner F, Klenerman P, Tighe PJ, Ryder S, Ball JK, Thomson BJ, Irving WL, Robins RA.

Eur J Immunol. 2001 Aug;31(8):2388-94.

29.

Viruses and apoptosis.

Thomson BJ.

Int J Exp Pathol. 2001 Apr;82(2):65-76. Review.

30.

Viruses and cancer.

Irving WL, Thomson BJ.

Int J Exp Pathol. 2001 Feb;82(1):1. No abstract available.

31.

Development of a strand-specific RT-PCR based assay to detect the replicative form of hepatitis C virus RNA.

Craggs JK, Ball JK, Thomson BJ, Irving WL, Grabowska AM.

J Virol Methods. 2001 May;94(1-2):111-20.

PMID:
11337045
32.

Possible ancient oceans on Mars: evidence from Mars Orbiter Laser Altimeter data.

Head JW 3rd, Hiesinger H, Ivanov MA, Kreslavsky MA, Pratt S, Thomson BJ.

Science. 1999 Dec 10;286(5447):2134-7.

33.

TT virus sequence heterogeneity in vivo: evidence for co-infection with multiple genetic types.

Ball JK, Curran R, Berridge S, Grabowska AM, Jameson CL, Thomson BJ, Irving WL, Sharp PM.

J Gen Virol. 1999 Jul;80 ( Pt 7):1759-68.

PMID:
10423145
34.

TT virus infection in patients with hepatitis C: frequency, persistence, and sequence heterogeneity.

Irving WL, Ball JK, Berridge S, Curran R, Grabowska AM, Jameson CL, Neal KR, Ryder SD, Thomson BJ.

J Infect Dis. 1999 Jul;180(1):27-34.

PMID:
10353857
35.

Low incidence of human herpesvirus 8 in stem cell collections from myeloma patients.

Cull GM, Carter GI, Timms JM, Thomson BJ, Russell NH, Haynes AP.

Bone Marrow Transplant. 1999 Apr;23(8):759-61.

36.

Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8.

Cull GM, Timms JM, Haynes AP, Russell NH, Irving WL, Ball JK, Thomson BJ.

Br J Haematol. 1998 Mar;100(4):793-6.

PMID:
9531351
37.

Q fever in pregnancy.

Ludlam H, Wreghitt TG, Thornton S, Thomson BJ, Bishop NJ, Coomber S, Cunniffe J.

J Infect. 1997 Jan;34(1):75-8.

PMID:
9120330
38.

The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution.

Gompels UA, Nicholas J, Lawrence G, Jones M, Thomson BJ, Martin ME, Efstathiou S, Craxton M, Macaulay HA.

Virology. 1995 May 10;209(1):29-51. Review.

41.

Lymphotropic viruses in 'common variable' immunodeficiency--PCR analysis of lymphocyte DNA for HIV-1 and HHV-6.

Sa'Adu A, Thomson BJ, Bountiff L, Webster AD.

Clin Exp Immunol. 1993 Jan;91(1):50-3.

43.

Identification of a transactivating function mapping to the putative immediate-early locus of human herpesvirus 6.

Martin ME, Nicholas J, Thomson BJ, Newman C, Honess RW.

J Virol. 1991 Oct;65(10):5381-90.

44.

Superantigen function.

Thomson BJ, Nicholas J.

Nature. 1991 Jun 13;351(6327):530. No abstract available.

PMID:
1646400
45.

Heart rate variability and cardiac arrhythmias in patients with chronic renal failure.

Thomson BJ, McAreavey D, Neilson JM, Winney RJ, Ewing DJ.

Clin Auton Res. 1991 Jun;1(2):131-3.

PMID:
1822760
46.

Acquisition of the human adeno-associated virus type-2 rep gene by human herpesvirus type-6.

Thomson BJ, Efstathiou S, Honess RW.

Nature. 1991 May 2;351(6321):78-80.

PMID:
1851252
47.

The genome of human herpesvirus 6: maps of unit-length and concatemeric genomes for nine restriction endonucleases.

Martin ME, Thomson BJ, Honess RW, Craxton MA, Gompels UA, Liu MY, Littler E, Arrand JR, Teo I, Jones MD.

J Gen Virol. 1991 Jan;72 ( Pt 1):157-68.

PMID:
1846644
48.

Detection by PCR of HHV-6 and EBV DNA in blood and oropharynx of healthy adults and HIV-seropositives.

Gopal MR, Thomson BJ, Fox J, Tedder RS, Honess RW.

Lancet. 1990 Jun 30;335(8705):1598-9. No abstract available.

PMID:
1972522
49.

Human retroviruses.

Thomson BJ, Dalgleish AG.

Blood Rev. 1988 Dec;2(4):211-21. Review.

PMID:
2905180
50.

Myocardial involvement in systemic lupus erythematosus detected by magnetic resonance imaging.

Been M, Thomson BJ, Smith MA, Ridgway JP, Douglas RH, Been M, Best JJ, Muir AL.

Eur Heart J. 1988 Nov;9(11):1250-6.

PMID:
3234418

Supplemental Content

Loading ...
Support Center